Lumexa Imaging Holdings, Inc. LMRI
- Market cap
- $949.2M
- P/E
- 0.0×
Follow LMRI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 15.81 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 19.45 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 4,335 | 5,019 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 936 | 949 | 1,023 |
Revenue
|
|||
| — | — | — | — | — | — | — | 10.57% | 10.15% | 15.40% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (119) | (79) | (32) |
EBT
|
|||
| — | — | — | — | — | — | — | (12.74%) | (8.35%) | (3.15%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (122) | (94) | (47) |
Net Income
|
|||
| — | — | — | — | — | — | — | 97 | 63 | 62 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 13.48 | 13.66 | 14.41 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (1.76) | (1.35) | (0.66) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.54 | 0.59 | 0.24 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.35) | (0.39) | (0.29) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | 0.19 | 0.19 | (0.05) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 2.33 | 8.26 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 69 | 69 | 71 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 7.97 | 7.97 | 2.24 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | 246.79 | 246.79 | (293.46) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | 38 | 41 | 17 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (24) | (27) | (21) |
Capex
|
|||
| — | — | — | — | — | — | — | 14 | 13 | (4) |
FCF
|
|||
| — | — | — | — | — | — | — | — | (1) | 48 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 1,217 | 865 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | 1,191 | 807 |
Net Debt
|
|||
| — | — | — | — | — | — | — | 0 | 162 | 586 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (11.27%) | (2.74%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 2.55% | 4.39% |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | (12.60%) |
ROE
|
|||
Lumexa Imaging Holdings, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CBLL CeriBell, Inc. | $914.2M | 0.0× | Compare |
| PRCT PROCEPT BioRobotics Corporation | $1.0B | 0.0× | Compare |
| ENOV Enovis Corporation | $1.1B | 0.0× | Compare |
| TNDM Tandem Diabetes Care, Inc. | $1.1B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SIBN SiBone | $830.0M | 0.0× | Compare |
| IRMD iRadimed Corporation | $1.1B | 47.1× | Compare |
| INMD InMode Ltd. | $815.7M | 11.4× | Compare |
| AORT Artivion, Inc. | $1.1B | 0.0× | Compare |
Lumexa Imaging Holdings, Inc. (LMRI) key facts
- Lumexa Imaging Holdings, Inc. (LMRI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Lumexa Imaging Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.82% from fiscal 2024.
- Lumexa Imaging Holdings, Inc. reported a net loss of $47.1 million, or a loss of $0.66 per share, for fiscal 2025.
- As of September 25, 2026, LMRI traded at $10.21, a market capitalization of $949.2 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.5× sales.
- Return on equity was −12.6% and debt-to-equity 1.42.
Lumexa Imaging Holdings, Inc. (LMRI) Latest News
20 Sep
Lumexa Imaging Holdings (LMRI) has drawn investor attention after recent share-price pressure: the stock is down about 4% for the week, roughly 11% over the past month, and down about 37% year-to-date, though a 90-day rebound sits around 16.75%. A widely followed view is that LMRI is about 36% undervalued versus a fair value estimate near $17.29, based on expectations that its outpatient imaging platform can lift capacity. Adoption of AI-enabled FastScan and a virtual cockpit MRI aims to raise scanner throughput by roughly 40%, cut downtime, extend hours, and improve margins and cash generation without proportional labor or equipment spend. Yet the upside hinges on continued referrals growth and de novo center rollout, and a slowdown could reset sentiment. The report also suggests comparing with healthcare peers to gauge resilience. AI-enabled throughput gains could materially shift LMRI's capacity, margins and cash flow, potentially altering its trajectory if the plan executes.
19 Aug
Lumexa Imaging Holdings, Inc. (LMRI) released its Q2 2026 earnings call transcript covering financial results, operations, and outlook. Earnings call transcript delivers financial results and guidance that can significantly shift LMRI stock trajectory and sentiment.
13 Aug
LMRI posted record advanced modality results in its Q2 2026 earnings call, driving stronger operational metrics and market positioning. Record advanced modality achievements indicate major revenue acceleration and competitive gains for LMRI.
12 Aug
Lumexa Imaging Holdings, Inc. (LMRI) shared key points from its Q2 earnings call covering financial results and operational updates. Q2 earnings results and outlook typically drive major shifts in stock valuation and investor sentiment.
Lumexa Imaging Holdings, Inc. (LMRI) announced its second quarter 2026 financial results. Quarterly earnings reports supply key financial metrics that affect valuation and market sentiment.
8 Jul
UG outperformed the industry over the past 6 months, raising buy, sell or hold questions for LMRI stock. Six-month outperformance metric may shift near-term investor views on LMRI without altering core operations.
11 Jun
Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) is nearing breakeven in its financial performance. Nearing breakeven indicates improving profitability for Lumexa Imaging Holdings, Inc.
2 Jun
Lumexa Imaging Holdings, Inc. forms joint venture with Hospital for Special Surgery to expand advanced outpatient imaging services in New York. Joint venture with HSS expands LMRI operations and strengthens market position in New York.
1 Jun
Lumexa Imaging Holdings, Inc. (LMRI) released its Q4 2025 earnings transcript covering financial results, operational updates, and outlook. Quarterly earnings transcript delivers financial metrics and guidance that can move near-term investor sentiment for LMRI.
14 May
Lumexa Imaging Holdings, Inc. (LMRI) released Q1 2026 earnings call transcript. Q1 2026 earnings transcript reveals financial results and guidance significantly influencing LMRI's trajectory and investor sentiment.
13 May
Lumexa Imaging Holdings Inc (LMRI) Q1 2026 earnings call highlights revenue growth and key operational updates. Revenue growth in Q1 2026 earnings call signals major positive shift in financial performance and market trajectory for LMRI.
12 May
Lumexa Imaging Holdings, Inc. (LMRI) released Q1 earnings call highlights covering financial results, operational updates, and future outlook. Q1 earnings highlights detail financial performance and strategic initiatives with potential to significantly influence LMRI's market trajectory and investor sentiment.
Lumexa Imaging Holdings, Inc. (LMRI) announced first quarter 2026 financial results. Quarterly earnings announcements directly impact financial performance metrics, investor sentiment, and stock trajectory.
Lumexa Imaging Holdings, Inc. (LMRI) advances its growth strategy by adding four new imaging centers. Adding four new imaging centers expands operational footprint and drives revenue growth potential.
20 Apr
Lumexa Imaging Holdings, Inc. (LMRI) appoints Kyle Lynch as Chief Growth Officer to lead expansion efforts and strategic initiatives. Appointing a Chief Growth Officer signals a major strategic push for expansion that could significantly alter LMRI's trajectory and investor sentiment.
26 Mar
Lumexa Imaging Holdings announced fourth quarter and full-year 2025 financial results and reiterated full-year 2026 guidance. Q4 and full-year earnings release with reaffirmed guidance delivers key financial data shaping investor sentiment and stock trajectory.
Lumexa Imaging Holdings, Inc. (LMRI) released highlights from its Q4 earnings call, covering financial results, operational updates, and future outlook. Q4 earnings call highlights directly address financial performance and guidance, moderately influencing investor sentiment and stock trajectory.
Lumexa Imaging Holdings, Inc. (LMRI) released its Q4 earnings snapshot. Q4 earnings snapshots provide key financial metrics that moderately influence LMRI's market performance and investor sentiment.
2 Mar
Lumexa Imaging Holdings, Inc. (LMRI) announced preliminary unaudited fourth quarter and full-year 2025 results, provided 2026 financial guidance, and scheduled an earnings conference call. Preliminary results and 2026 guidance directly shape investor expectations, stock valuation, and future trajectory.
25 Feb
Raymond James upgraded Lumexa Imaging Holdings, Inc. (LMRI) to Strong Buy, keeping the $23 price target unchanged. Raymond James' upgrade to Strong Buy enhances investor sentiment and could drive significant positive shifts in LMRI's stock performance.
28 Jan
Dr. Jennifer L. Kemp of Lumexa Imaging Holdings, Inc. has been elected to the Board of the Radiological Society of North America (RSNA). This appointment is expected to enhance national leadership in quality and patient-centered care within the radiology field, reflecting Lumexa's commitment to advancing healthcare standards. The election of Dr. Kemp to the RSNA Board may positively influence Lumexa's reputation and strategic positioning in the healthcare sector.
15 Jan
Lumexa Imaging Holdings, Inc. (LMRI) has experienced a notable share price pullback, prompting a reassessment of its valuation. Analysts are evaluating the company's financial health and market position in light of recent developments. The pullback may present a buying opportunity for investors, depending on the company's future performance and strategic initiatives. The share price pullback indicates potential challenges that could moderately influence financial performance and market sentiment.
8 Jan
Lumexa Imaging Holdings, Inc. (LMRI) has achieved a record de novo expansion in 2025, significantly increasing its operational footprint and market presence. This expansion is expected to enhance the company's capabilities and drive future growth, positioning it favorably within the imaging sector. The strategic move reflects Lumexa's commitment to innovation and responsiveness to market demands, potentially leading to improved financial performance and competitive advantages. The record de novo expansion is likely to significantly impact Lumexa's future performance and market positioning.
15 Dec
Lumexa Imaging Holdings, Inc. (LMRI) has experienced a recent dip in share price, raising questions about its valuation. Analysts are assessing whether the decline reflects a temporary market reaction or indicates deeper issues within the company. Investors are urged to consider the company's fundamentals and market position before making decisions. The share price dip may affect investor sentiment and financial performance, but the overall impact is expected to be limited.
10 Dec
Lumexa Imaging Holdings, Inc. has announced the pricing of its initial public offering (IPO), setting the price at $10 per share. The company aims to raise approximately $50 million through the offering, which will be used to fund its growth initiatives and operational expenses. The IPO is expected to enhance Lumexa's visibility in the market and provide capital for further development of its imaging technologies. The IPO is a significant strategic move that could enhance the company's market position and investor sentiment.